Doripenem is a broad-spectrum antibiotic in the β-lactam subclass known as carbapenems.
1,2 It is active against Gram-negative and Gram-positive bacteria, including
S. aureus,
S. pneumoniae,
E. coli, and
K. pneumoniae (MICs = 0.03-0.06, 0.016-0.06, <0.015-0.3, and 0.03-0.06 μg/ml, respectively).
1,2,3,4 Doripenem reduces the number of viable bacteria in mouse lung in a model of chronic
P. aeruginosa respiratory tract infection when administered at a dose of 100 mg/kg per day.
5 It inhibits bacterial cell wall synthesis by forming stable acyl enzymes with penicillin-binding proteins, thereby inactivating them.
2 Formulations containing doripenem have been used in the treatment of bacterial infections.
1. Mandell, L. Doripenem: A new carbapenem in the treatment of nosocomial infection Clin. Infect. Dis. 49(Suppl 1),S1-S3(2009).
2. Paterson, D.L., and DePestel, D.D. Doripenem Clin. Infect. Dis. 49(2),291-298(2009).
3. Papp-Wallace, K.M., Endimiani, A., Taracila, M.A., et al. Carbapenems: Past, present, and future Antimicrob. Agents Chemother. 55(11),4943-4960(2011).
4. El Solh, A.A., and Alhajhusain, A. Update on the treatment of Pseudomonas aeruginosa pneumonia J. Antimicrob. Chemother. 64(2),229-238(2009).
5. Araki, N., Yanagihara, K., Morinaga, Y., et al. In vivo efficacy of doripenem (DRPM) against Pseudomonas aeruginosa in murine chronic respiratory tract infection model J. Infect. Chemother. 17(3),318-321(2011).
